Hülya GÜVEN, M. Aylin ARICI, Gözde AKTÜRK, Özge GÜNER

A Case Report of a Pregnant Woman with Chronic Hepatit B: Use of Tenofovir in Pregnancy

Objective: To overview the effects of tenofovir use in chronic Hepatit B in pregnancy and asses the effects on the vertical transmission of HBV from mother to baby. Case Report: We presented a pregnant woman who has Chronic Hepatit B with high viral load in the 26th week of her pregnancy. She took tenofovir in the 37th week of her pregnancy once a day along six days. Then she gave birth to a healthy baby at the 37th week of the pregnancy. Hepatit B Immunoglobulin (HBIG) and Hepatit B vaccine had applied to the baby. In the follow-up, the mother’s viral load was decreased. HBV DNA was not detected in the baby. Conclusion: Only six-day tenofovir use in this pregnant woman with chronic Hepatit B may contribute to preventing vertical transmission of HBV from mother to baby. However, the importance of HBIG and vaccination should not be forgotten.

PDF

___

1. Ehrhardt S, Xie C, Guo N, Nelson K, Thio CL. Breastfeeding while taking lamivudine or tenofovir disoproxil fumarate: a review of the evidence. Clin Infect Dis 2015;60:275–278. [CrossRef ]
2. Gentile I, Borgia G. Vertical transmission of hepatitis B virus: challenges and solutions. Int J Womens Health 2014;6:605. [CrossRef ]
3. Celen MK, Mert D, Ay M, et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection. World J Gastroenterol 2013;19:9377–9382. [CrossRef ]
4. Wakano Y, Sugiura T, Endo T, et al. Antiviral therapy for hepatitis B virus during second pregnancies. J Obstet Gynaecol Res 2018;44:566–569. [CrossRef ]
5. Kwon H, Lok AS. Viral hepatitis and pregnancy. Clin Liver Dis 2014;4:55–57. [CrossRef ]
6. Pan CQ, Mi L, Bunchorntavakul C, et al. Tenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis B virus infection by highly viremic pregnant women: a case series. Dig Dis Sci 2012;57:2423–2429. [CrossRef ]
7. Ayoub WS, Cohen E. Hepatitis B management in the pregnant patient: An update. J Clin Transl Hepatol 2016;4:241–247. [CrossRef ]
8. Jaffe A, Brown RS. A review of antiviral use for the treatment of chronic hepatitis B virus infection in pregnant women. Gastroenterol Hepatol (N Y) 2017;13:154–163. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439134/pdf/GH_13_154.pdf
9. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry Interim Report for 1 January 1989 through 31 January 2018. Wilmington, NC. Registry Coordinating Center; 2017. Available from: http://www.apregistry.com/
10. Zeng J, Zheng C, Li H. Effectiveness of tenofovir or telbivudine in preventing HBV vertical transmission for pregnancy. Medicine (Baltimore) 2019;98:e15092. [CrossRef ]
11. Salvadori N, Fan B, Teeyasoontranon W, et al. Maternal and Infant Bone Mineral Density 1 Year After Delivery in a Randomized, Controlled Trial of Maternal Tenofovir Disoproxil Fumarate to Prevent Mother-to-child Transmission of Hepatitis B Virus. Clin Infect Dis 2019;69:144–146. [CrossRef ]
12. Bzowej NH. Optimal management of the hepatitis B patient who desires pregnancy or is pregnant. Curr Hepat Rep 2012;11:82–89. [CrossRef ]
13. Greenup A, Tan PK, Nguyen V, et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus. J Hepatol 2014;61:502–507. https:// [CrossRef ]
14. Jourdain G, Ngo-Giang-Huong N, Harrison L, et al. Tenofovir versus placebo to prevent perinatal transmission of hepatitis B. N Engl J Med 2018;378:911–923. [CrossRef ]
15. Zhang L, Gui X, Wang B, et al. A study of immunoprophylaxis failure and risk factors of hepatitis B virus mother-to-infant transmission. Eur J Pediatr 2014;173:1161–1168. [CrossRef ]